In a report released on August 13, Thomas Smith from Leerink Partners reiterated a Buy rating on Kyverna Therapeutics, Inc., with a price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Smith has given his Buy rating due to a combination of factors related to Kyverna Therapeutics, Inc.’s promising clinical progress and strategic plans. The company is on track with its pivotal KYSA-8 trial in stiff person syndrome (SPS), aiming for a Biologics License Application (BLA) submission in the first half of 2026. This trial, which has completed enrollment, is focused on patients with positive GAD65 antibody titers, and early indicators suggest a meaningful clinical impact.
Additionally, Kyverna is advancing its myasthenia gravis (MG) program, with interim Phase 2 data expected by the end of 2025 and plans to initiate a Phase 3 trial by year-end. The company’s broader neuroimmunology franchise, including potential in lupus nephritis and multiple sclerosis, further underscores its leadership in the autoimmune cell therapy field. These developments, coupled with positive early clinical data and a differentiated CAR construct, contribute to a favorable outlook for Kyverna Therapeutics.
Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aclaris Therapeutics, and Eledon Pharmaceuticals. According to TipRanks, Smith has an average return of 43.3% and a 54.21% success rate on recommended stocks.
In another report released on August 13, Morgan Stanley also maintained a Buy rating on the stock with a $20.00 price target.